Ellis Keith, Brener Sorin
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
Cleve Clin J Med. 2004 Jan;71(1):20, 23-5, 29-30 passim. doi: 10.3949/ccjm.71.1.20.
The efficacy and safety of fibrinolytic agents have not dramatically changed since alteplase (Activase), a derivative of tissue plasminogen activator (t-PA), was introduced nearly 2 decades ago. However, newer agents have a longer half-life, making them easier to deliver. Fibrinolytic therapy is underused in many patients, especially in those traditionally thought to be at high risk for complications.
自从大约20年前引入组织纤溶酶原激活剂（t-PA）的衍生物阿替普酶（爱通立）以来，纤溶药物的疗效和安全性并没有显著改变。然而，新型药物的半衰期更长，使其更易于给药。纤溶治疗在许多患者中未得到充分应用，尤其是那些传统上被认为并发症风险较高的患者。
